This year’s Sareum Plc (SAR) AGM was held at the offices of Citigate Dewe Rogerson, 3 London Wall Buildings, London Wall, London EC2M 5S, on Tuesday December 18th commencing at 10:00
For investors who are unfamiliar with the company, SAR is a small biopharmaceutical company specialising in identifying and developing small molecule kinase inhibitors which would ideally be suitable for both iv. and oral administration. Target indications include various cancer types and auto immune diseases such as lupus, RA and psoriasis. SAR currently has four compounds at various stages of development.
SAR was founded in 2003 by a group of senior managers from the US biotech Millennium Pharmaceuticals, this followed the closure of Millennium’s operations in the UK in order to concentrate their business in the United States (note Millennium were subsequently acquired by Japanese Pharma Takeda, in 2008).
SAR listed on AIM in October 2004 raising…
Click here for the complete AGM report if you are a full member of ShareSoc, as these reports are exclusive to our full members. The above is only an introduction to the full report, which contains much more information. Further information about access to our AGM reports can be found here.